CTAD 2022 and Biomarkers View overview page

Remaining challenges in bringing fluid biomarkers into clinical practice

Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis

Bringing the pTau/Aβ42 biomarker into the clinic

Promise of microRNAs as Alzheimer’s disease markers

The importance of using systems biology based approaches in AD research

Mild behavioral impairment is associated with abnormal AD CSF biomarker profiles in MCI

Highlights from CTAD 2022

Clinical implementations of AlzoSure Predict

Blood-based biomarkers as surrogates of amyloid burden in preclinical Alzheimer’s disease

Predicting tau-PET signal in early Alzheimer’s disease using speech biomarkers

Promise of exosomal proteins as biomarkers in Alzheimer’s disease

Speech biomarker for cognition: a novel marker for AD clinical trial screening

Is amyloid load a valid surrogate endpoint for AD clinical trials?

Astrocyte biomarkers associated with amyloid-β and tau pathologies

Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease

Associations between predicted brain age and Alzheimer’s Disease biomarkers